Stocksigma LogoStocksigma Logo

Marksans Pharma Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million)

■ Revenue: 9,402 (+30.5% YoY | +11.8% QoQ) ■ EBITDA: 2,143 (+48.3% YoY | +0.6% QoQ) ■ EBITDA Margin (%): 22.8 (+274 bps YoY | -254 bps QoQ) ■ PAT: 1,413

Marksans Pharma Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million)

Marksans Pharma Ltd · Outcome · 04 Nov 2026, 6:57 pm

Marksans Pharma Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 9,402 (+30.5% YoY | +11.8% QoQ) ■ EBITDA: 2,143 (+48.3% YoY | +0.6% QoQ) ■ EBITDA Margin (%): 22.8 (+274 bps YoY | -254 bps QoQ) ■ PAT: 1,413 (+43.8% YoY | -10.1% QoQ) ■ EPS (INR): 3.11 (+43.3% YoY | -10.4% QoQ)

Original exchange filing (PDF)

More announcements from Marksans Pharma Ltd

All Marksans Pharma Ltd announcements